A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of One 150 mg Risedronate [risedronic acid] Tablet Versus Two 75 mg Risedronate Tablets Administered as a Single Oral Dose in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2013
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors Procter & Gamble
- 24 Mar 2010 Warner-Chilcott added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
- 14 Jul 2008 New trial record.